Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Altimmune Inc (NQ: ALT )

7.195 -0.375 (-4.95%)
Streaming Delayed Price Updated: 11:16 AM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Altimmune Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
These weight loss drug stocks are relatively unknown and brimming with potential following the massive success of Novo Nordisk and Eli Lilly. 
Via InvestorPlace
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
The GLP-1 weight loss trend continues to flourish, and the ante keeps rising; see how the winner between Wegovy and Zepbound can help your portfolio 
Via MarketBeat
Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential
Altimmune has a modest market cap but an incredibly promising GLP-1 drug. 
Via The Motley Fool
3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024
Biotech stocks can offer some of the most explosive, exciting opportunities on the market.That is, if you find the right one. 
Via InvestorPlace
Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.
Viking Therapeutics has garnered a lot of attention following a successful clinical trial for its obesity care drug. But another development-stage biotech may have a superior candidate. 
Via The Motley Fool
How Is The Market Feeling About Altimmune?
Via Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have $300 Today
Via Benzinga
ALT Stock Earnings: Altimmune Beats EPS for Q4 2023
ALT stock results show that Altimmune beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?
Altimmune has a GLP-1 candidate in Phase 2 trials, but the company continues to burn cash and may need a big pharma partner to get its drug to market 
Via MarketBeat
Exposures Product Safety
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-expected fourth-quarter loss. Kodiak Sciences posted a quarterly loss of... 
Via Benzinga
Altimmune's Earnings Outlook
Via Benzinga
(ALT) - Analyzing Altimmune's Short Interest
Via Benzinga
Here's How Much $100 Invested In Altimmune 5 Years Ago Would Be Worth Today
Via Benzinga
Here's How Much $100 Invested In Altimmune 5 Years Ago Would Be Worth Today
Via Benzinga
REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday
U.S. stocks were slightly higher, with the S&P 500 gaining around 0.1% on Thursday. Shares of REX American Resources Corporation (NYSE: REX) rose sharply during Thursday’s session following upbeat... 
Via Benzinga
Stock Market Rally Shows Breadth As Leaders Take A Breath: Weekly Review
The stock market rally showed breadth, with small caps leading the way to a 24-month high. Growth leaders like Nvidia took a break. 
Via Investor's Business Daily
7 Stocks That Will Drive the Weight Loss Drugs Market
The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis. 
Via MarketBeat
Why Is Obesity Drug Developer Altimmune Stock Trading Lower On Wednesday?
Latest findings on Altimmune's pemvidutide on body composition: lean mass preservation, significant weight loss from adipose tissue, and results in obesity and Metabolic dysfunction-associated... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Earnings Scheduled For March 27, 2024
Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million. 
Via Benzinga
Cramer Calls Datadog 'Dynamite,' Puts SoFi In Dog House: 'What The Heck Is Going On'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Marvell Technology, Inc. (NASDAQ: MRVL) reported a mixed quarter. 
Via Benzinga
Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?
Viking Therapeutics just might be an attractive acquisition target for Pfizer. 
Via The Motley Fool
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
WHY: NEW YORK, NY - (NewMediaWire) - March 03, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Altimmune,... 
Via NewMediaWire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
WHY: NEW YORK, NY - (NewMediaWire) - March 03, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Altimmune,... 
Via TheNewswire.com
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
WHY: NEW YORK, NY - (NewMediaWire) - March 01, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Altimmune,... 
Via TheNewswire.com
Stock Market Rally At Highs After Big Earnings, Inflation Data: Weekly Review
The Nasdaq is on the cusp of setting a record high. 
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
ALT LOSS ALERT: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ALT LOSS ALERT: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
WHY: NEW YORK, NY - (NewMediaWire) - February 27, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Altimmune,... 
Via TheNewswire.com
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.